**Dr. Dan T. Dransfield, PhD**

Senior Vice President, Research & Development

Siamab Therapeutics, Inc.
Newton, MA 02458

"Developing Novel Glycan-Targeted Cancer Immunotherapies"

**Abstract:** Siamab’s proprietary technology platform enables the development of highly specific mAb therapeutics, including ADCs, bi-specific antibodies and CAR-T cell therapies, targeting cancer cell surface glycans called tumor-associated carbohydrate antigens (TACAs). TACAs are an emerging set of tumor antigens that are implicated in immune suppression, chemo-resistance and a cancer stem cell (CSC) phenotype. The elevated presence of STn—a key TACA observed in a number of solid tumors, including ovarian, prostate, pancreatic, gastric, and colon—is associated with metastatic disease, poor prognosis, and reduced overall survival. Elevation of STn expression is linked to chemotherapy resistance and enables tumors to evade the host immune system. In addition, STn is expressed on multiple biomarkers including the CSC biomarkers CD44 and MUC1, which reside on both CSCs and mature malignant cells in some cancer types. The seminar will focus on the discovery and development of ST1, a selective anti-STn antibody drug conjugate for the treatment of STn+ cancers.

**Wednesday April 4th, 2018**

4:00 pm
WO 1205

Inquiries can be made of:
Dr. Peter R. Andreana @ 419-530-1930
peter.andreana@utoledo.edu